Induction and maintenance immunosuppression in lung transplantation

Area of Science:

• Immunology
• Transplantation Medicine
• Pharmacology

Background:

• Immunosuppression is vital for lung transplant recipients to prevent acute and chronic rejection.
• Standard protocols involve induction and maintenance immunotherapy.
• Induction agents offer immediate immunosuppression, with basiliximab being commonly used.

Purpose of the Study:

• To review current immunosuppression strategies for lung transplant recipients.
• To discuss available induction and maintenance agents.
• To highlight the importance of tailored dosing and future research directions.

Main Methods:

• Review of current clinical practices and available literature on immunosuppression protocols.
• Analysis of commonly used induction agents (e.g., basiliximab) and maintenance therapies (e.g., tacrolimus, mycophenolate mofetil, prednisone).
• Consideration of patient-specific factors influencing treatment regimens.

Main Results:

• Basiliximab is a frequently employed induction agent.
• Maintenance therapy typically involves a calcineurin inhibitor, anti-metabolite, and corticosteroid.
• Dosing and target levels are individualized based on patient status and time post-transplant.

Conclusions:

• Current immunosuppression protocols are based on established agents and individualized dosing.
• Awareness of agent-specific side effects is crucial.
• Future studies are needed to optimize induction and maintenance regimens, with current practices guided by registry data.